GlassScriptPhysician profile
Michelle Polan
NPI 1689835209
$2,630.32
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $746 · 2020: $991 · 2021: $318 · 2022: $421 · 2023: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $155.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $760.00 | 2020 | |
| Biomarin Pharmaceutical INC. | $349.80 | 2019-2022 | |
| Genzyme Corporation | $265.47 | 2019-2023 | |
| Eisai INC. | $241.14 | 2019-2021 | |
| Amicus Therapeutics, INC. | $158.65 | 2022-2023 | Galafold |
| Sunovion Pharmaceuticals INC. | $121.16 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $114.02 | 2019-2022 | |
| Livanova USA, INC. | $96.96 | 2019-2021 | |
| Ucb, INC. | $76.23 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $64.88 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $56.51 | 2019-2021 | |
| Ptc Therapeutics, INC. | $46.99 | 2020-2022 | |
| Ultragenyx Pharmaceutical INC. | $39.75 | 2021-2023 | |
| Aquestive Therapeutics, INC. | $36.72 | 2020-2021 | |
| Biogen, INC. | $35.05 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $31.94 | 2019-2023 | Vpriv |
| Vanda Pharmaceuticals INC. | $28.84 | 2021 | |
| Duchesnay USA Incorporated | $23.32 | 2022 | |
| Greenwich Biosciences, INC. | $20.62 | 2019 | |
| Neurelis, INC. | $17.85 | 2020 | |
| Alnylam Pharmaceuticals INC. | $16.07 | 2022 | |
| Ns Pharma, INC. | $15.33 | 2021 | |
| Rhodes Pharmaceuticals L.P. | $13.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Polan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.